Journal Description
Neuroglia
Neuroglia
is an international, peer-reviewed, open access journal on Neuroscience published quarterly online by MDPI.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.6 days after submission; acceptance to publication is undertaken in 6 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Latest Articles
The Neuroimmunological Nexus of Multiple Sclerosis: Deciphering the Microglial Transcriptomic Tapestry
Neuroglia 2024, 5(3), 234-253; https://doi.org/10.3390/neuroglia5030017 - 20 Jul 2024
Abstract
►
Show Figures
Microglia are poorly understood immune cells of the central nervous system that play a determining role in the progression of multiple sclerosis. With the advent of genomic techniques such as single-cell RNA sequencing and single-nucleus RNA sequencing, a more comprehensive understanding of microglia
[...] Read more.
Microglia are poorly understood immune cells of the central nervous system that play a determining role in the progression of multiple sclerosis. With the advent of genomic techniques such as single-cell RNA sequencing and single-nucleus RNA sequencing, a more comprehensive understanding of microglia at the transcriptomic level has uncovered various disease-specific clusters, context-dependent heterogeneity, and region-specific microglia, unlocking the recondite secrets embedded within these glial cells. These techniques have raised questions regarding the conventional and widely accepted categorization of microglia as M1 and M2 phenotypes. The neuroimmune component of multiple sclerosis, which is the microglia, makes it a complex and challenging disease. This review aims to demystify the complexities of microglia in multiple sclerosis, providing a vivid map of different clusters and subclusters of microglia found in multiple sclerosis and outlining the current knowledge of the distinctive roles of microglia. Also, this review highlights the neuroimmune interaction with microglia as the epicenter and how they act as sabotaging agents. Moreover, this will provide a more comprehensive direction toward a treatment approach focusing on local, region-specific microglia.
Full article
Open AccessOpinion
Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma
by
Richard E. Kast
Neuroglia 2024, 5(3), 223-233; https://doi.org/10.3390/neuroglia5030016 - 2 Jul 2024
Abstract
Glioblastomas synthesize, bear receptors for, and respond to bradykinin, triggering migration and proliferation. Since centrifugal migration into uninvolved surrounding brain tissue occurs early in the course of glioblastoma, this attribute defeats local treatment attempts and is the primary reason current treatments almost always
[...] Read more.
Glioblastomas synthesize, bear receptors for, and respond to bradykinin, triggering migration and proliferation. Since centrifugal migration into uninvolved surrounding brain tissue occurs early in the course of glioblastoma, this attribute defeats local treatment attempts and is the primary reason current treatments almost always fail. Stopping bradykinin-triggered migration would be a step closer to control of this disease. The recent approval and marketing of an oral plasma kallikrein inhibitor, berotralstat (Orladeyo™), and pending FDA approval of a similar drug, sebetralstat, now offers a potential method for reducing local bradykinin production at sites of bradykinin-mediated glioblastoma migration. Both drugs are approved for treating hereditary angioedema. They are ideal for repurposing as a treatment adjunct in glioblastoma. Furthermore, it has been established that peritumoral edema, a common problem during the clinical course of glioblastoma, is generated in large part by locally produced bradykinin via kallikrein action. Both brain edema and the consequent use of corticosteroids both shorten survival in glioblastoma. Therefore, by (i) migration inhibition, (ii) growth inhibition, (iii) edema reduction, and (iv) the potential for less use of corticosteroids, berotralstat may be of service in treatment of glioblastoma, slowing disease progression. This paper recounts the details and past research on bradykinin in glioblastoma and the rationale of treating it with berotralstat.
Full article
(This article belongs to the Special Issue Glioblastoma (GBM) Brain Tumor Invasion and Consequences on Diagnosis, Clinical Strategies and Therapy)
►▼
Show Figures
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00016/article_deploy/html/images/neuroglia-05-00016-g001-550.jpg?1719897422)
Figure 1
Open AccessArticle
Xc- System as a Possible Target for ConBr Lectin Interaction in Glioma Cells
by
Vanir Reis Pinto-Junior, Rodrigo Lopes Seeger, Cláudio Henrique Dahne Souza-Filho, Angela Patricia França, Nicole Sartori, Messias Vital Oliveira, Vinicius Jose Silva Osterne, Kyria Santiago Nascimento, Rodrigo Bainy Leal and Benildo Sousa Cavada
Neuroglia 2024, 5(3), 202-222; https://doi.org/10.3390/neuroglia5030015 - 1 Jul 2024
Abstract
►▼
Show Figures
Studies have revealed the dependence of glioma cells on iron, making them sensitive to ferroptosis. Ferroptosis can be triggered by inhibition of the xc- system, resulting in redox imbalance and membrane lipid peroxidation. The xc- system is composed of two coupled proteins, xCT
[...] Read more.
Studies have revealed the dependence of glioma cells on iron, making them sensitive to ferroptosis. Ferroptosis can be triggered by inhibition of the xc- system, resulting in redox imbalance and membrane lipid peroxidation. The xc- system is composed of two coupled proteins, xCT and CD98hc. The control of transporters, such as xCT, by the CD98hc glycoprotein suggests that molecules targeting glycans may have an impact on the treatment of glioma. This study evaluated the effect of the Canavalia brasiliensis (ConBr) lectin on C6 glioma cells and compared it with erastin, an xc- system inhibitor. Both induced dose-dependent cell death, accompanied by an increase in the production of reactive oxygen species and a decrease in reduced glutathione. However, co-treatment did not show an additive effect. The analysis was updated by molecular dynamics assessments of the xc- system interacting with ConBr or erastin. The interaction of erastin with the xc- system affects its interaction with ConBr, reducing the antagonistic effect when both are in the protein complex. The data show that ConBr is effective in inducing cell death in glioma cells and regulates the xc system through interaction with CD98hc glycans, showing that lectins have the potential to promote ferroptosis in glioma cells.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00015/article_deploy/html/images/neuroglia-05-00015-ag-550.jpg?1719832862)
Graphical abstract
Open AccessArticle
Telmisartan Reduces LPS-Mediated Inflammation and Induces Autophagy of Microglia
by
Kwame O. Affram, Zachary C. Janatpour, Nagesh Shanbhag, Sonia Villapol and Aviva J. Symes
Neuroglia 2024, 5(2), 182-201; https://doi.org/10.3390/neuroglia5020014 - 20 Jun 2024
Abstract
►▼
Show Figures
Background: Chronic neuroinflammation mediated by persistent microglial activation is strongly linked to neurodegeneration. Therefore, targeting microglial activation could be beneficial in treating neurodegenerative disorders. Angiotensin receptor blockers (ARBs), commonly prescribed for high blood pressure, exhibit prominent anti-inflammatory effects in the brain and are
[...] Read more.
Background: Chronic neuroinflammation mediated by persistent microglial activation is strongly linked to neurodegeneration. Therefore, targeting microglial activation could be beneficial in treating neurodegenerative disorders. Angiotensin receptor blockers (ARBs), commonly prescribed for high blood pressure, exhibit prominent anti-inflammatory effects in the brain and are considered potential therapies for neurodegenerative diseases and neurotrauma. Although all ARBs are angiotensin II receptor type I antagonists, some ARBs act through other signaling pathways, allowing for multiple mechanisms of action. The anti-inflammatory mechanisms of ARBs are not well understood. Methods: In this study, we compared eight different FDA-approved ARBs for their ability to reduce the LPS stimulation of primary microglia or BV2 cells through analyses of nitric oxide production, reactive oxygen species generation, and the mRNA of proinflammatory cytokines. Finding specific and unique effects of telmisartan, we interrogated signaling pathways and other downstream effectors of telmisartan activity on microglia. Results: Our findings indicate that telmisartan showed the greatest efficacy in reducing the LPS induction of reactive oxygen species (ROS) and nitric oxide production in microglia. Uniquely amongst ARBs, telmisartan activated AMPK phosphorylation and inhibited mTOR phosphorylation. Telmisartan’s anti-inflammatory activity was partially inhibited by the AMPK inhibitor compound C. Furthermore, telmisartan uniquely induced markers of autophagy in microglia through an AMPK–mTOR–autophagy pathway. Telmisartan also reduced microglial viability. Telmisartan’s cytotoxicity was partially ameliorated by an autophagy inhibitor and a pan-caspase inhibitor, indicating a link between microglial autophagy and apoptosis. Conclusions: We conclude that telmisartan has unique properties relative to other ARBs, including potent anti-inflammatory actions and an induction of microglial autophagy, which may enable specific therapeutic uses.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00014/article_deploy/html/images/neuroglia-05-00014-g001-550.jpg?1718866236)
Figure 1
Open AccessReview
Left-Parietal Angiocentric Glioma: Our Experience and a Review of the Literature
by
Antonello Curcio, Shervin Espahbodinea, Eva Azzurra Li Trenta, Rosamaria Ferrarotto, Aristide Nanni, Noemi Arabia, Giorgio Ciccolo, Giovanni Raffa, Francesca Granata and Antonino Germanò
Neuroglia 2024, 5(2), 165-181; https://doi.org/10.3390/neuroglia5020013 - 1 Jun 2024
Abstract
►▼
Show Figures
Background: Angiocentric glioma (AG) is a rare, benign, and slow-growing tumor. First described in 2005, it is now gaining attention with respect to the possibility of being diagnosed. Even with no statistical differences between sex, it has been reported both in children and
[...] Read more.
Background: Angiocentric glioma (AG) is a rare, benign, and slow-growing tumor. First described in 2005, it is now gaining attention with respect to the possibility of being diagnosed. Even with no statistical differences between sex, it has been reported both in children and the elderly. A total of 120 cases have been described in the literature. The aim of this study is to provide new data for a new statistical assessment of the prevalence and incidence of AG in populations. Case report: An 8-year-old male patient with no history of epilepsy and no need for antiepileptic therapy underwent surgery for a left-parietal brain lesion, revealed through MRI. Imaging was acquired after his first absence episode. The lesion was completely resected. Histological findings indicated angiocentric glioma. No signs of recurrency after two years of follow-up. Conclusion: AG is usually an epilepsy-related low-grade glioma. Few cases exhibit disease progression and exitus. Surgical management should aim for a gross total resection to avoid recurrence and persisting epilepsy. Surgery represents the gold standard in diagnosis and treatment and must be performed as soon as possible in consideration of its healing properties and its useful diagnosis.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00013/article_deploy/html/images/neuroglia-05-00013-g001-550.jpg?1717333055)
Figure 1
Open AccessReview
How Schwann Cells Are Involved in Brain Metastasis
by
JuliAnne Allgood, Avery Roe and Jessica E. Pullan
Neuroglia 2024, 5(2), 155-164; https://doi.org/10.3390/neuroglia5020012 - 1 Jun 2024
Abstract
►▼
Show Figures
The current lack of a comprehensive understanding of brain metastasis mechanisms presents a significant gap in cancer research. This review outlines the role that Schwann cells (SCs) have in this process. SCs are already known for their role in myelination and nerve repair
[...] Read more.
The current lack of a comprehensive understanding of brain metastasis mechanisms presents a significant gap in cancer research. This review outlines the role that Schwann cells (SCs) have in this process. SCs are already known for their role in myelination and nerve repair within the peripheral nervous system (PNS), but there is less information on their function in facilitating the transport and activation of neoplastic cells to aid in the invasion of the blood–brain barrier and brain. Detailed insights into SCs’ interactions with various cancers, including lung, breast, melanoma, colon, kidney, and pancreatic cancers, reveal how these cells are coerced into repair-like phenotypes to accelerate cancer spread and modulate immune responses. By outlining SCs’ involvement in perineural invasion and BBB modification, this review highlights their functions in facilitating brain metastasis.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00012/article_deploy/html/images/neuroglia-05-00012-g001-550.jpg?1717230650)
Figure 1
Open AccessArticle
Prediction of Glioma Resistance to Immune Checkpoint Inhibitors Based on Mutation Profile
by
Guillaume Mestrallet
Neuroglia 2024, 5(2), 145-154; https://doi.org/10.3390/neuroglia5020011 - 27 May 2024
Abstract
►▼
Show Figures
Glioma, a highly aggressive cancer, presents a daunting prognosis, with only 5% of glioblastoma patients surviving beyond five years post diagnosis. Current therapeutic strategies, including surgical intervention, radiotherapy, chemotherapy, and immune checkpoint blockade (ICB), while promising, often encounter limited efficacy, particularly in glioblastoma
[...] Read more.
Glioma, a highly aggressive cancer, presents a daunting prognosis, with only 5% of glioblastoma patients surviving beyond five years post diagnosis. Current therapeutic strategies, including surgical intervention, radiotherapy, chemotherapy, and immune checkpoint blockade (ICB), while promising, often encounter limited efficacy, particularly in glioblastoma cases. Addressing this challenge requires a proactive approach to anticipate treatment response and resistance. In this study, we analyzed 117 glioma patients who underwent ICB treatment to uncover the mechanisms underlying treatment resistance. Through a meticulous examination of mutational profiles post ICB, we identified several mutations associated with varied survival outcomes. Notably, mutations such as STAG2 Missense, EGFR A289V Missense, TP53 Nonsense, and RB1 FS del were linked to prolonged overall survival, while others, including IF del, FAT1 E1206Tfs*4 FS del, PDGFRA FS del, PIK3R1 M326Vfs*6 FS del, Y463* Nonsense, NF1 Missense, and R1534*, were associated with poorer survival post ICB. Leveraging these insights, we employed machine learning algorithms to develop predictive models. Remarkably, our model accurately forecasted glioma patient survival post ICB within an error of 4 months based on their distinct mutational profiles. In conclusion, our study advocates for personalized immunotherapy approaches in glioma patients. By integrating patient-specific attributes and computational predictions, we present a promising avenue for optimizing clinical outcomes in immunotherapy.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00011/article_deploy/html/images/neuroglia-05-00011-g001-550.jpg?1716795620)
Figure 1
Open AccessArticle
Flow Cytometry Characterization and Analysis of Glial and Immune Cells from the Spinal Cord
by
Lilian de Oliveira Coser, Manuela Tosi Comelis, Débora Elisa da Costa Matoso, Luciana Politti Cartarozzi and Alexandre Leite Rodrigues de Oliveira
Neuroglia 2024, 5(2), 129-144; https://doi.org/10.3390/neuroglia5020010 - 20 May 2024
Abstract
►▼
Show Figures
Several protocols have been developed with the aim of characterizing glial and immune cells from the central and peripheral nervous systems. However, a small number of these protocols have demonstrated the ability to yield satisfactory results following conventional isolation. Considering this necessity and
[...] Read more.
Several protocols have been developed with the aim of characterizing glial and immune cells from the central and peripheral nervous systems. However, a small number of these protocols have demonstrated the ability to yield satisfactory results following conventional isolation. Considering this necessity and the difficulties encountered in enzymatic and bead isolation, our work proposes a method for the isolation of glial and immune cells from the spinal cord utilizing a Percoll gradient. For this purpose, C57BL/6J spinal cords were dissected, and the lumbar intumescence was dissociated and subjected to a Percoll gradient centrifugation (70%, 50%, 37%, and 10%). Each layer was then separated and labeled for astrocytes (anti-GFAP, TNF-α, IFN-γ, IL-10, IL-4), microglia (anti-CD45, CD11b, CD206, CD68, TNF-α, IFN-γ), and lymphocytes (anti-CD3, CD4, IFN-γ, IL-4). The gate detections were mathematically performed by computational analysis utilizing the K-means clustering algorithm. The results demonstrated that astrocytes were concentrated at the Percoll 10/37 interface, microglia at the Percoll 37/50 layer, and lymphocytes at the Percoll 50/70 layer. Our findings indicate that astrocytes in healthy animals are putative of the A1 profile, while microglia and lymphocytes are more frequently labeled with M1 and Th1 markers, suggesting a propensity towards inflammatory responses. The computational method enabled the semi-autonomous gate detection of flow cytometry data, which might facilitate and expedite the processing of large amounts of data.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00010/article_deploy/html/images/neuroglia-05-00010-g001-550.jpg?1716198191)
Figure 1
Open AccessReview
Microglial Dyshomeostasis: A Common Substrate in Neurodevelopmental and Neurodegenerative Diseases
by
Vada Andree Furlan, Daria MacAuslan, Khiem Ha, Nitish Patel, Shawn Adam, Beylem Zanagar and Sharmila Venugopal
Neuroglia 2024, 5(2), 119-128; https://doi.org/10.3390/neuroglia5020009 - 12 May 2024
Abstract
►▼
Show Figures
Neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD) are clinically distinct, yet share synaptic dysfunction as a common brain pathophysiology. Neurodegenerative diseases such as Huntington’s disease (HD) entail a neuroinflammatory cascade of molecular and cellular events which can
[...] Read more.
Neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD) are clinically distinct, yet share synaptic dysfunction as a common brain pathophysiology. Neurodegenerative diseases such as Huntington’s disease (HD) entail a neuroinflammatory cascade of molecular and cellular events which can contribute to the death of neurons. Emerging roles for supportive glial cells such as microglia and astrocytes in the ongoing regulation of neural synapses and brain excitability raise the possibility that some of the synaptic pathology and/or inflammatory events could be a direct consequence of malfunctioning glial cells. Focusing on microglia, we cross-examined 12 recently published studies in which microglial dysfunction was induced/identified in a cell-autonomous manner and its functional consequence on neural development, brain volume, functional connectivity, inflammatory response and synaptic regulation were evaluated; in many cases, the onset of symptoms relevant to all three neurodevelopmental disorders were assessed behaviorally. Challenging the classic notion of microglial activation as an inflammatory response to neuropathology, our compilation clarifies that microglial dyshomeostasis itself can consequently disrupt neural homeostasis, leading to neuropathology and symptom onset. This further warranted defining the molecular signatures of context-specific microglial pathology relevant to human diseases.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00009/article_deploy/html/images/neuroglia-05-00009-g001-550.jpg?1715504354)
Figure 1
Open AccessSystematic Review
Brain Tumor Recognition Using Artificial Intelligence Neural-Networks (BRAIN): A Cost-Effective Clean-Energy Platform
by
Muhammad S. Ghauri, Jen-Yeu Wang, Akshay J. Reddy, Talha Shabbir, Ethan Tabaie and Javed Siddiqi
Neuroglia 2024, 5(2), 105-118; https://doi.org/10.3390/neuroglia5020008 - 28 Apr 2024
Abstract
►▼
Show Figures
Brain tumors necessitate swift detection and classification for optimal patient outcomes. Deep learning has been extensively utilized to recognize complex tumor patterns in magnetic resonance imaging (MRI) images, aiding in tumor diagnosis, treatment, and prognostication. However, model complexity and limited generalizability with unfamiliar
[...] Read more.
Brain tumors necessitate swift detection and classification for optimal patient outcomes. Deep learning has been extensively utilized to recognize complex tumor patterns in magnetic resonance imaging (MRI) images, aiding in tumor diagnosis, treatment, and prognostication. However, model complexity and limited generalizability with unfamiliar data hinder appropriate clinical integration. The objective of this study is to develop a clean-energy cloud-based deep learning platform to classify brain tumors. Three datasets of a total of 2611 axial MRI images were used to train our multi-layer convolutional neural network (CNN). Our platform automatically optimized every transfer learning and data augmentation feature combination to provide the highest predictive accuracy for our classification task. Our proposed system identified and classified brain tumors successfully and efficiently with an overall precision value of 96.8% [95% CI; 93.8–97.6]. Using clean energy supercomputing resources and cloud platforms cut our workflow to 103 min, $0 in total cost, and a negligible carbon footprint (0.0014 kg eq CO2). By leveraging automated optimized learning, we developed a cost-effective deep learning (DL) platform that accurately classified brain tumors from axial MRI images of different levels. Although studies have identified machine learning tools to overcome these obstacles, only some are cost-effective, generalizable, and usable regardless of experience.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00008/article_deploy/html/images/neuroglia-05-00008-g001-550.jpg?1714298018)
Figure 1
Open AccessReview
Microbiome-Glia Crosstalk: Bridging the Communication Divide in the Central Nervous System
by
Mitra Tabatabaee
Neuroglia 2024, 5(2), 89-104; https://doi.org/10.3390/neuroglia5020007 - 21 Apr 2024
Abstract
►▼
Show Figures
The traditional neuron-centric view of the central nervous system (CNS) is shifting toward recognizing the importance of communication between the neurons and the network of glial cells. This shift is leading to a more comprehensive understanding of how glial cells contribute to CNS
[...] Read more.
The traditional neuron-centric view of the central nervous system (CNS) is shifting toward recognizing the importance of communication between the neurons and the network of glial cells. This shift is leading to a more comprehensive understanding of how glial cells contribute to CNS function. Alongside this shift, recent discoveries have illuminated the significant role of the human microbiome, comprising trillions of microorganisms, mirroring the number of human cells in an individual. This paper delves into the multifaceted functions of neuroglia, or glial cells, which extend far beyond their traditional roles of supporting and protecting neurons. Neuroglia modulate synaptic activity, insulate axons, support neurogenesis and synaptic plasticity, respond to injury and inflammation, and engage in phagocytosis. Meanwhile, the microbiome, long overlooked, emerges as a crucial player in brain functionality akin to glial cells. This review aims to underscore the importance of the interaction between glial cells and resident microorganisms in shaping the development and function of the human brain, a concept that has been less studied. Through a comprehensive examination of existing literature, we discuss the mechanisms by which glial cells interface with the microbiome, offering insights into the contribution of this relationship to neural homeostasis and health. Furthermore, we discuss the implications of dysbiosis within this interaction, highlighting its potential contribution to neurological disorders and paving the way for novel therapeutic interventions targeting both glial cells and the microbiome.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00007/article_deploy/html/images/neuroglia-05-00007-ag-550.jpg?1714032254)
Graphical abstract
Open AccessCommunication
Metformin Reduces Viability and Inhibits the Immunoinflammatory Profile of Human Glioblastoma Multiforme Cells
by
Daewoo Hong, Regina Ambe, Jose Barragan, Kristina Marie Reyes and Jorge Cervantes
Neuroglia 2024, 5(2), 80-88; https://doi.org/10.3390/neuroglia5020006 - 31 Mar 2024
Abstract
Glioblastoma (GBM) is the predominant primary malignant brain tumor. Metformin, a well-known antidiabetic medication, has emerged as a potential therapeutic candidate in the treatment of GBM. We have herein investigated two aspects of the effect of MTF on GBM cells: the effect of
[...] Read more.
Glioblastoma (GBM) is the predominant primary malignant brain tumor. Metformin, a well-known antidiabetic medication, has emerged as a potential therapeutic candidate in the treatment of GBM. We have herein investigated two aspects of the effect of MTF on GBM cells: the effect of MTF on GBM cell viability, as previous studies have shown that MTF can selectively affect human GBM tumors; and the immunomodulatory effect of MTF on GBM, as there is evidence that inflammation is associated with GBM growth and progression. The human GBM cell line (U87) was exposed to various doses of MTF (1 mM, 20 mM, and 50 mM), followed by examination of cell viability and inflammatory mediator secretion at various time points. We observed that MTF treatment exerted a dose-response effect on glioblastoma multiforme cell viability. It also had an immunomodulatory effect on GBM cells. Our study identified several mechanisms that led to the overall inhibitory effect of MTF on human GBM. Further inquiry is necessary to gain a better understanding of how these in vitro findings would translate into successful in vivo approaches.
Full article
(This article belongs to the Special Issue Glioblastoma (GBM) Brain Tumor Invasion and Consequences on Diagnosis, Clinical Strategies and Therapy)
►▼
Show Figures
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00006/article_deploy/html/images/neuroglia-05-00006-g001-550.jpg?1711882921)
Figure 1
Open AccessReview
Ketogenic Diet in the Management of Glioblastomas: A Bibliometric Analysis
by
Alexandros G. Brotis, Christina Arvaniti, Marina Kontou, Alexandros Tsekouras and Kostas N. Fountas
Neuroglia 2024, 5(2), 63-79; https://doi.org/10.3390/neuroglia5020005 - 22 Mar 2024
Abstract
Glioblastoma is a highly aggressive brain tumor that has a poor prognosis despite various treatments like surgery, chemotherapy, and irradiation. However, a restricted ketogenic diet (RKD), which has been proven to be effective in treating drug-resistant epilepsy, could be a potential adjunct in
[...] Read more.
Glioblastoma is a highly aggressive brain tumor that has a poor prognosis despite various treatments like surgery, chemotherapy, and irradiation. However, a restricted ketogenic diet (RKD), which has been proven to be effective in treating drug-resistant epilepsy, could be a potential adjunct in the treatment of certain GBM cases. Our study aimed to highlight the existing knowledge, identify collaboration networks, and emphasize the ongoing research based on highly cited studies. During the literature search, we found 119 relevant articles written between 2010 and 2023. Among the top 20 most cited articles, there were seven laboratory and five clinical studies. The works of Olson LK, Chang HT, Schwartz KA, and Nikolai M from the Michigan State University, followed by Seyfried TN and Mukherjee P from Boston College, and Olieman JF, and Catsman-Berrevoets CE from the University Medical Center of Rotterdam, were significant contributions. The laboratory studies showed that RKD had a significant antitumor effect and could prolong survival in mouse glioblastoma models. The clinical studies verified the tolerability, efficacy, and safety of RKD in patients with GBM, but raised concerns about whether it could be used as a single therapy. The current research interest is focused on the efficacy of using RKD as an adjunct in selected chemotherapy regimens and demonstrates that it could provide GBM patients with better treatment options.
Full article
(This article belongs to the Special Issue Glioblastoma (GBM) Brain Tumor Invasion and Consequences on Diagnosis, Clinical Strategies and Therapy)
►▼
Show Figures
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00005/article_deploy/html/images/neuroglia-05-00005-g001-550.jpg?1711093436)
Figure 1
Open AccessReview
Primary Co-Occurrence of Gonadal and Extragonadal Central Nervous System (CNS) Germ Cell Tumors (GCTs): Case Report and Review of the Literature
by
Francesco Tengattini, Cesare Francesco Soffiati, Pier Paolo Panciani, Marco Zeppieri, Tamara Ius, Shahan Momjian, Karl Schaller, Marco Maria Fontanella and Lucio De Maria
Neuroglia 2024, 5(1), 50-62; https://doi.org/10.3390/neuroglia5010004 - 21 Mar 2024
Abstract
►▼
Show Figures
Background: The primary co-occurrence of gonadal and extragonadal central nervous system (CNS) germ cell tumors (GCTs) has rarely been reported in the literature, and a common opinion on the underlying etiopathogenetic mechanism is lacking. Objective: We aim to investigate the pathophysiological mechanisms and
[...] Read more.
Background: The primary co-occurrence of gonadal and extragonadal central nervous system (CNS) germ cell tumors (GCTs) has rarely been reported in the literature, and a common opinion on the underlying etiopathogenetic mechanism is lacking. Objective: We aim to investigate the pathophysiological mechanisms and genetic pathways underlying the primary co-occurrence of gonadal and CNS GCTs. Methods: We reviewed data from 29 consecutive patients with a diagnosis of CNS GCT, evaluated in our Hospital over the past 23 years, and searched for those who had at least a primary gonadal co-occurrence of GCT. A systematic review of the literature according to the PRISMA guidelines was also conducted. For a comprehensive and detailed search, PubMed, Ovid MEDLINE, and Ovid EMBASE databases have been consulted. Boolean operators and MeSH terms were used to find studies. Only articles published between 2000 and 2023 were considered. Results: Including our Institutional case report, a total of 7 patients with both testicular NGGCTs and CNS GCTs were identified (5 patients with metachronous tumors and patients with synchronous presentation). The average age at tumor diagnosis was 17 years. The cerebral histotypes reported were mixed GCTs (3 cases; 43%), pure germinomas (3 cases, 43%), and one yolk sac tumor (14%). Two out of seven cases (29%) were syndromic, one suffering from Down Syndrome and the other from Testicular Dysgenesis Syndrome. Regarding the etiology and molecular mechanism of GCT development, several gene mutations have been reported in the literature. Particularly, genetic alterations in the MAPK and/or PI3K/AKT/mTOR pathway, together with mutations of the KIT gene, have been shown to guarantee survival and transformation of mismigrated totipotent primordial germ cells, while suppressor genes allow their resistance against apoptotic death. Aberrant chromosomes have also been reported to be responsible for oncogenic transformation. It is also known that CNS and testicular GCTs share some genetic/epigenetic profiles. Conclusions: The primary co-occurrence of testicular NGGCT and extragonadal CNS GCTs is extremely rare. Genetic factors seem to play a paramount role in their etiopathogenesis. Additional research is needed to elucidate molecular mechanisms of oncogenesis in such patients.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00004/article_deploy/html/images/neuroglia-05-00004-g001-550.jpg?1711086469)
Figure 1
Open AccessReview
The Relevance of Astrocytic Cell Culture Models for Neuroinflammation in Neurodegeneration Research
by
André Maciel Preato, Ester da Silva Pinheiro, Tatiana Rosado Rosenstock and Isaias Glezer
Neuroglia 2024, 5(1), 27-49; https://doi.org/10.3390/neuroglia5010003 - 29 Feb 2024
Abstract
►▼
Show Figures
Astrocytes are the predominant glial cells that provide essential support to neurons and promote microenvironment changes in neuropathological states. Astrocyte and astrocytic-like cell culture have substantially contributed to elucidating the molecular pathways involved in key glial roles, including those relevant to neurodevelopment, brain
[...] Read more.
Astrocytes are the predominant glial cells that provide essential support to neurons and promote microenvironment changes in neuropathological states. Astrocyte and astrocytic-like cell culture have substantially contributed to elucidating the molecular pathways involved in key glial roles, including those relevant to neurodevelopment, brain physiology and metabolism, which are not readily accessible with traditional approaches. The in vitro methodology has also been applied to neuroinflammatory and neurodegeneration contexts, revealing cellular changes involved in brain dysfunction. Astrocytes studies in culture started with primary cell approaches using embryonic and postmortem tissue. Further developments included newborn rodent primary cells, cell lines and immortalized astrocytes, which resulted in homogeneous cell-type preparations grown on flat surfaces. To overcome some in vitro shortcomings, tridimensional bioprinted models and organoid culture enabled the mimicking of tissue cellular arrangements and, above these achievements, complex astrocyte cell culture can be generated from induced pluripotent stem cells (iPSCs) to model diseases. These unprecedented breakthroughs allowed the development of platforms to test new therapies in brain cells derived from human material noninvasively obtained from live patients. In this work, we reviewed the most studied astrocytic cell models for discussing limitations, advantages and reliable experimental readouts for neuroinflammation in neurodegeneration research.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00003/article_deploy/html/images/neuroglia-05-00003-ag-550.jpg?1709191832)
Graphical abstract
Open AccessReview
The Role of Neuroglia in Administrating Nerve Blockers and Anesthesia to Patients
by
Anjali Patel, Raja Al-Bahou, Rajvi Thakkar, Drashti Patel, Devon Foster, Jonathan Benjamin, Marian Pedreira and Brandon Lucke-Wold
Neuroglia 2024, 5(1), 13-26; https://doi.org/10.3390/neuroglia5010002 - 29 Jan 2024
Abstract
►▼
Show Figures
Dysfunction of the neuroglia can have profound consequences on the blood–brain barrier (BBB). Studies have shown that the disruption of astrocytic–endothelial interaction can compromise the permeability of BBB and its effectiveness in selectively regulating the exchange of substances. Microglia have recently been recognized
[...] Read more.
Dysfunction of the neuroglia can have profound consequences on the blood–brain barrier (BBB). Studies have shown that the disruption of astrocytic–endothelial interaction can compromise the permeability of BBB and its effectiveness in selectively regulating the exchange of substances. Microglia have recently been recognized to have a significant role in the initiation of chronic pain and in its interactions with various nerve blockers and anesthetic agents. Microglia have a role in pain resolution via a pathway that involves Cannabinoid receptor type 2 activation and MAP kinase phosphorylation. Understanding the role of these cells in the context of neuropathic pain and neurological disorders can aid in improving clinical outcomes and the challenging nature of managing pain. Advancing studies have proposed pharmacological and genetic modulation of microglia as a potential treatment option for patients with chronic pain.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-05-00002/article_deploy/html/images/neuroglia-05-00002-g001-550.jpg?1706513562)
Figure 1
Open AccessPerspective
Contribution of Small Extracellular Vesicles from Schwann Cells and Satellite Glial Cells to Pain Processing
by
Parisa Gazerani
Neuroglia 2024, 5(1), 1-12; https://doi.org/10.3390/neuroglia5010001 - 28 Jan 2024
Abstract
Extracellular vesicles (EVs), including exosomes and microvesicles, are membrane-bound particles released by cells into extracellular space. These vesicles carry various molecules, such as proteins and lipids, and can serve as mediators of intercellular communication. EVs have been implicated in the communication between different
[...] Read more.
Extracellular vesicles (EVs), including exosomes and microvesicles, are membrane-bound particles released by cells into extracellular space. These vesicles carry various molecules, such as proteins and lipids, and can serve as mediators of intercellular communication. EVs have been implicated in the communication between different cell types in the nervous system, for instance, the neurons and glial cells of the central nervous system (CNS) and peripheral nervous system (PNS). Satellite glial cells (SGCs) surround and support neurons in the sensory ganglia of the PNS, and it has been proposed that the EVs released by SGCs may contribute to the processing of pain-related signals and features. This includes the modulation of neuronal activity, the release of pro-inflammatory signaling molecules, and sensitization. A noticeable finding is that EVs can transfer bioactive molecules, including proteins and microRNAs (miRNAs), between cells, influencing cellular functions such as gene expression regulation involved in the transmission and modulation of pain signals. Schwann cells (SCs) also release EVs. SC-derived EVs sequester TNFR1, influencing TNFα activity and regulating neuroinflammation in peripheral nerve injuries. Understanding peripheral glia’s EVs role in pain processing is an emerging area in neuroscience. Here, the latest findings, challenges, and potential are presented to encourage future research.
Full article
(This article belongs to the Special Issue Exclusive Papers Collection of Editorial Board Members in Neuroglia)
Open AccessReview
Protoplasmic Perivascular Astrocytes Play a Crucial Role in the Development of Enlarged Perivascular Spaces in Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus
by
Melvin R. Hayden
Neuroglia 2023, 4(4), 307-328; https://doi.org/10.3390/neuroglia4040021 - 1 Dec 2023
Cited by 1
Abstract
Astrocytes (ACs) are the most abundant cells in the brain and, importantly, are the master connecting and communicating cells that provide structural and functional support for brain cells at all levels of organization. Further, they are recognized as the guardians and housekeepers of
[...] Read more.
Astrocytes (ACs) are the most abundant cells in the brain and, importantly, are the master connecting and communicating cells that provide structural and functional support for brain cells at all levels of organization. Further, they are recognized as the guardians and housekeepers of the brain. Protoplasmic perivascular astrocyte endfeet and their basal lamina form the delimiting outermost barrier (glia limitans) of the perivascular spaces in postcapillary venules and are important for the clearance of metabolic waste. They comprise the glymphatic system, which is critically dependent on proper waste removal by the pvACef polarized aquaporin-4 water channels. Also, the protoplasmic perisynaptic astrocyte endfeet (psACef) are important in cradling the neuronal synapses that serve to maintain homeostasis and serve a functional and supportive role in synaptic transmission. Enlarged perivascular spaces (EPVS) are emerging as important aberrant findings on magnetic resonance imaging (MRI), and are associated with white matter hyperintensities, lacunes, and aging, and are accepted as biomarkers for cerebral small vessel disease, increased obesity, metabolic syndrome, and type 2 diabetes. Knowledge is exponentially expanding regarding EPVS along with the glymphatic system, since EPVS are closely associated with impaired glymphatic function and waste removal from the brain to the cerebrospinal fluid and systemic circulation. This review intends to focus on how the pvACef play a crucial role in the development of EPVS.
Full article
(This article belongs to the Special Issue Exclusive Papers Collection of Editorial Board Members in Neuroglia)
►▼
Show Figures
![](https://pub.mdpi-res.com/neuroglia/neuroglia-04-00021/article_deploy/html/images/neuroglia-04-00021-g001-550.jpg?1701415047)
Figure 1
Open AccessArticle
Aging-Related Changes in Expression and Function of Glutamate Transporters in Rat Spinal Cord Astrocytes
by
Shiksha Sharan, Bhanu Prakash Tewari and Preeti G. Joshi
Neuroglia 2023, 4(4), 290-306; https://doi.org/10.3390/neuroglia4040020 - 24 Nov 2023
Abstract
►▼
Show Figures
Astrocytes make up the predominant cell population among glial cells in the mammalian brain, and they play a vital role in ensuring its optimal functioning. They promote neuronal health and survival and protect neurons from glutamate-induced excitotoxicity. In the spinal cord’s dorsal horn
[...] Read more.
Astrocytes make up the predominant cell population among glial cells in the mammalian brain, and they play a vital role in ensuring its optimal functioning. They promote neuronal health and survival and protect neurons from glutamate-induced excitotoxicity. In the spinal cord’s dorsal horn (DH) and ventral horn (VH) regions, astrocytes serve crucial roles. Notably, VH motor neurons exhibit a heightened sensitivity to glutamate-induced damage. It is posited that this selective sensitivity could be related to their localized presence within the VH, where astrocytes possess a distinct set of mechanisms for managing glutamate. As organisms age, the risk of damage from glutamate increases, indicating a potential decline in the efficiency of astrocytic glutamate regulation. Our research involved an analysis of astrocytic structure, glutamate transporter levels, and glutamate uptake capabilities within the DH and VH through immunohistochemical methods, protein analysis via Western blot, and patch-clamp studies in electrophysiology. The investigations revealed a decrease in both the number and coverage of astroglia in the spinal cord, more so within the VH as aging progressed. Notably, levels of the excitatory amino acid transporters 1 and 2 (EAAT1 and EAAT2) also decreased with age, particularly within the VH. Patch-clamp analyses of astrocytes from both spinal regions confirmed a significant reduction in glutamate uptake activity as age advanced, indicating an age-related impairment in glutamate processing. The findings indicate aging leads to distinct changes in DH and VH astrocytes, impairing their glutamate management abilities, which could contribute significantly to the development of late-onset neurodegenerative conditions.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-04-00020/article_deploy/html/images/neuroglia-04-00020-g001-550.jpg?1702267534)
Figure 1
Open AccessArticle
Comparison of the Transduction Capacity of AAV5 and AAV PHP.eB Serotypes in Hippocampus Astroglia
by
Anastasia Borodinova, Victor Ierusalimsky and Pavel Balaban
Neuroglia 2023, 4(4), 275-289; https://doi.org/10.3390/neuroglia4040019 - 1 Nov 2023
Abstract
►▼
Show Figures
In the present study, we compared the astrocyte-transducing potential of the relatively novel engineered AAV PHP.eB serotype and the well-examined conventional AAV5 serotype. We generated the AAV-based genetic constructs with membrane-bound fluorescent markers under the control of the astroglial promoter GfaABC1D to target
[...] Read more.
In the present study, we compared the astrocyte-transducing potential of the relatively novel engineered AAV PHP.eB serotype and the well-examined conventional AAV5 serotype. We generated the AAV-based genetic constructs with membrane-bound fluorescent markers under the control of the astroglial promoter GfaABC1D to target astrocytes in vivo, either via local injection into the hippocampus (AAV5, AAV PHP.eB) or via systemic injection in the retro-orbital venous sinus (AAV PHP.eB). We collected new data on the transduction properties of locally injected PHP.eB and AAV5 viruses. A morphological examination and immunostainings of mouse brain slices revealed a dose-dependent shift of cellular tropism for locally injected PHP.eB from astroglial to astroglial-neuronal as the concentration increased. When the high doses of PHP.eB viruses were administered systemically, we observed strong astrocyte transduction throughout the brain, as confirmed by the morphological examination and GFAP immunostaining. AAV5 exhibited consistent astrocytic expression in all tested concentrations. The obtained results suggest that AAV5 is more suitable for astrocyte targeting in routine stereotaxic viral injection experiments. The widely used engineered PHP.eB capsid was originally designed for the transduction of both neurons and glia. Dual cellular tropism of PHP.eB viruses, observed using different doses and different delivery protocols (local vs. systemic), suggests that the usage of AAV5 is more reliable for astrocyte labeling and that intrahippocampal injection is more suitable than systemic injection for the preferential labeling of hippocampal astroglia.
Full article
![](https://pub.mdpi-res.com/neuroglia/neuroglia-04-00019/article_deploy/html/images/neuroglia-04-00019-g001-550.jpg?1698825742)
Figure 1
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
![loading...](https://pub.mdpi-res.com/img/loading_circle.gif?9a82694213036313?1721979229)
Conferences
Special Issues
Special Issue in
Neuroglia
Glioblastoma (GBM) Brain Tumor Invasion and Consequences on Diagnosis, Clinical Strategies and Therapy
Guest Editors: Mauro Palmieri, Alessandro PesceDeadline: 31 August 2024